Omezol

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Omezol

Defining Omezol: Identity, Class, and Composition

Property Description
Active ingredient Omeprazole
Form Delayed-release capsule (enteric-coated pellets)
Pharmacological class Proton Pump Inhibitor (PPI)
General use Reduction of gastric acid secretion
Origin Synthetic (Substituted benzimidazole)

The medicine Omezol contains the active ingredient Omeprazole, which is classified pharmacologically as a Proton Pump Inhibitor (PPI). The substance Omeprazole is a synthetic compound belonging to the substituted benzimidazole chemical family. Omeprazole is utilized for its role in profound acid suppression.


Physical Form and Delivery Type

Omezol is typically provided as a delayed-release capsule containing numerous tiny enteric-coated pellets. This specific pharmaceutical design is a critical requirement to ensure the drug's efficacy, as the Omeprazole compound is unstable and rapidly degraded when exposed to the high acidity of the stomach. The enteric coating protects the active ingredient, ensuring it passes safely into the small intestine where it can be absorbed and transported to the specific target cells for activation. These agents are designed for sustained acid suppression in the management of acid-related conditions.


Omezol's General Purpose: Why it Matters

The general therapeutic purpose of Omeprazole is the sustained control and reduction of gastric acid secretion. It achieves this by the irreversible inhibition of the proton pump, which is the specific enzyme responsible for the final stage of acid production in the stomach lining. By blocking this acid-producing machinery, the medicine lowers the overall acidity of the stomach. This reduction establishes a physiological environment that helps mitigate irritation and allows the protective mucosal lining of the gastrointestinal tract to recover from damage associated with excess acid.

Regulatory References

  1. MedlinePlus Drug Information

What side effects are possible with Omezol?

Possible side effects and safety information

The official regulatory safety profile for Omeprazole (Omezol) classifies adverse reactions based on frequency and the affected body system, as documented in regulatory sources like the FDA and EMA. The profile distinguishes between common, frequently observed events and rare, clinically significant reactions.

Frequency-Classified Adverse Reactions

The most frequently reported adverse effects in clinical trials are classified as common. These typically involve gastrointestinal disorders such as abdominal pain, diarrhea, nausea, vomiting, and flatulence, as well as headache. Reactions classified as uncommon include insomnia, rash, pruritus, and elevations in liver enzyme levels.

Serious Adverse Reactions and Duration-Related Safety

Official labeling notes several serious reactions documented, often through postmarketing surveillance. These include Acute Tubulointerstitial Nephritis (TIN), and severe skin reactions such as Severe Cutaneous Adverse Reactions (SCARs).

Specific safety characteristics are officially associated with long-term use. Prolonged administration may be linked to an increased risk of bone fracture (hip, wrist, or spine), low serum magnesium levels (Hypomagnesemia), the development of Fundic Gland Polyps, and potential Vitamin B-12 deficiency.

Population and Diagnostic Constraints

The safety profile for pediatric patients is generally considered similar to adults, though specific events like fever were reported frequently in studies. Regulatory documents also note that a symptomatic response to Omeprazole does not rule out the presence of serious underlying conditions, such as gastric malignancy. Furthermore, the medicine is associated with an increased risk of Clostridium difficile-Associated Diarrhea (CDAD) and may elevate Chromogranin A (CgA) levels, potentially interfering with diagnostic tests for neuroendocrine tumors.

Overdose and Emergency Response

Overdose and When to Seek Help

This section describes the officially documented manifestations and mandated actions in the event of an Omezol (Omeprazole) overdose, based strictly on government regulatory documents.


Documented Overdose Manifestations

Official prescribing information documents a range of clinical signs observed in cases of acute overdose, including high ingestions up to 900 mg. Reported manifestations often affect multiple systems and include headache, confusion, drowsiness, nausea, vomiting, abdominal pain, diarrhea, flushing, dry mouth, and tachycardia (rapid heart rate). Symptoms reported were typically transient, and no serious clinical outcome has been reported in connection with overdose.


Official Emergency Action

If an overdose is known or suspected, regulatory guidelines mandate that the patient must seek immediate medical attention or contact a Poison Control Center right away. The official management strategy is defined as symptomatic and supportive treatment. Importantly, no specific antidote for omeprazole overdosage is known. Due to the compound's extensive plasma protein binding, Omeprazole is not readily dialyzable, reinforcing the need for professional supportive care and continuous monitoring of vital signs.

Therapeutic Uses of Omezol

Omezol (Omeprazole) is a therapeutic agent generally used across several gastrointestinal domains where symptoms are driven by excessive stomach acid. It provides support through sustained acid reduction, which may contribute to significant symptomatic relief and supports the body’s healing processes. The medication is commonly used for a variety of acid-related conditions and symptoms.


Managing Chronic Heartburn and Reflux Disease

Omezol is commonly used to treat Gastroesophageal Reflux Disease (GERD) and the associated painful inflammation of the esophagus, known as erosive esophagitis. It helps address the frequent, disruptive symptoms related to physical discomfort like burning chest pain (heartburn) and the irritating acid regurgitation, which contributes to improved comfort during periods of heightened symptoms. The relevant indications include the management of GERD, supporting the recovery from and long-term stabilization of erosive esophagitis, and the management of pathological hypersecretory states.

“The primary benefit of Omeprazole is its ability to support the healing of acid-damaged tissues.”


Healing Ulcers and Protecting the Stomach Lining

The medication is applied in addressing conditions marked by increased physiological stress, such as active gastric or duodenal ulcers, to support the healing of the damaged tissue. Furthermore, it is considered relevant for individuals who require long-term treatment with Non-steroidal Anti-inflammatory Drugs (NSAIDs), offering support and playing a role in managing the risk of drug-induced stomach injury. This use helps improve day-to-day comfort during symptomatic periods and assists with maintaining functional stability.


Quick Fact: Relief for Burning Chest Pain Omezol may assist with managing the intensity and frequency of heartburn and regurgitation that interfere with sleep and routine activities.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Official Eligibility Status

Use of Omezol is defined by regulatory guidelines based on age, physiological status, and concurrent therapy. This information is derived strictly from official regulatory labeling, such as FDA and EMA documents.

Populations Permitted or Cleared for Use:

  • Adults and Older Adults: Approved for all labeled indications; dose adjustment is generally not required for older adults or patients with renal impairment.
  • Pediatric Patients: Approved for children one year of age and older for symptomatic GERD. Use for the treatment of Erosive Esophagitis is established for infants one month of age and older.
  • Pregnancy and Lactation: Official documentation indicates the medicine can be used during pregnancy and is not likely to influence the child during breastfeeding.

Populations with Absolute Contraindications (Use Prohibited):

  • Individuals with known hypersensitivity to omeprazole, to other substituted benzimidazoles, or to any formulation excipients.
  • Patients receiving co-treatment with the antiretroviral medicines nelfinavir or rilpivirine-containing products.
  • Patients with rare hereditary problems of fructose intolerance or glucose-galactose malabsorption.

Use-Related Restrictions and Caution:

  • Gastric Ulcer: The possibility of malignancy must be excluded before initiating therapy.
  • Severe Hepatic Impairment: Use requires caution, and a dosage reduction may be necessary.
  • Infants Under 1 Month: Safety and effectiveness have not been established in children younger than this age.
  • Concurrent Clopidogrel: Co-administration is discouraged or should be avoided due to a documented interaction.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Omezol’s interaction profile is officially documented to involve two main mechanisms: alterations in gastric pH and the inhibition of specific liver enzymes. This results in formal restrictions concerning co-administration with several medicinal products and substances.

Documented Interaction Patterns

Classification Interacting Medicines/Substances
Contraindicated Combinations Rilpivirine-containing products
Not Recommended/Avoid Combinations Nelfinavir, Atazanavir, Clopidogrel, Rifampin, St. John's Wort

Co-administration with Nelfinavir and Atazanavir is officially discouraged as Omezol significantly reduces their plasma concentrations due to pH-dependent absorption interference. Similarly, taking Omezol with Rilpivirine is a formal contraindication documented in regulatory prescribing information.

Pharmacokinetic and Pharmacodynamic Effects

Omezol is an inhibitor of the enzyme CYP2C19, a property that can prolong the systemic exposure of other medicines metabolized by this pathway, including Warfarin, Diazepam, and Phenytoin. Due to this effect, co-administration with the antiplatelet medicine Clopidogrel is officially discouraged because it may diminish its pharmacological activity, an effect noted to persist even when doses are separated by 12 hours.

Furthermore, Omezol can elevate the serum concentrations of other critical medicines like Methotrexate and Tacrolimus. The official labeling notes that patients with hepatic impairment or those identified as CYP2C19 poor metabolizers may experience increased systemic exposure to Omezol, which can amplify these interaction risks.

Mechanism of Action

️ Irreversible Blockade of the H^+/ K^+-ATPase

Omeprazole (Omezol) functions as an irreversible inhibitor by binding permanently to the Proton Pump ( H^+/ K^+-ATPase), the enzyme responsible for the final stage of acid production in the stomach's parietal cells. This action blocks the efflux of hydrogen ions ( H^+), resulting in a significant and sustained suppression of gastric acid secretion that is independent of the upstream physiological triggers.


Acid-Dependent Activation and Mechanism Duration

The drug is a prodrug that requires activation in the highly acidic microenvironment of the parietal cells before it can inhibit the pump. Because the inhibition is permanent (covalent), the effect lasts until the cell synthesizes new pumps, rather than being limited by the drug's clearance from the body. This unique enzyme turnover-dependent duration contributes to a sustained elevation of intragastric pH.


⏳ Mechanistic Limitations: The Role of New Pumps

While highly effective, the mechanism requires the proton pumps to be active for optimal inhibition. Furthermore, the sustained acid suppression leads to a compensatory rise in gastrin hormone, which stimulates the creation of new pumps. This process is a key mechanistic factor that dictates the full development of the physiological effect over a few days and is also the underlying cause of compensatory acid hypersecretion following cessation of the drug.

Dosage and Administration Information

How Omeprazole (Omezol) is Used: Administration Guidelines

Omeprazole use is defined by specific procedural instructions detailing the required route, dose, timing, and physical handling.


Administration Routes and Dosing Patterns

The primary method of administration is oral, typically via a delayed-release capsule. The intravenous (IV) route is an alternative reserved for short-term use in clinical settings when oral intake is not possible.

The standard frequency pattern for most conditions is once daily (OD). Doses typically range from 10 mg, 20 mg, or 40 mg daily. Regimens for pathological hypersecretory conditions, such as Zollinger-Ellison Syndrome, may require higher doses, sometimes up to 120 mg per day, often divided into twice daily (BID) use.


Procedural Instructions and Course Duration

To ensure proper delivery, the oral dose is generally directed to be taken before a meal, ideally in the morning. The delayed-release capsule must be swallowed whole with water. It is essential not to crush or chew the capsule or the pellets inside, as this compromises the necessary enteric coating.

Treatment courses are typically time-bound, lasting 4 to 8 weeks for initial healing of conditions like ulcers or erosive esophagitis. However, long-term use is established and indicated for maintenance therapy in specific chronic conditions.


Population-Specific Use

While no adjustment is typically required for older adults or patients with renal impairment, a dose reduction may be necessary for those with severe hepatic impairment. If a dose is missed, it should be taken as soon as remembered, but taking two doses simultaneously must be avoided.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Action and Function

The drug’s action in studies involves the inhibition of the H+, K+-ATPase enzyme, also known as the proton pump, in the stomach's parietal cells. This enzyme is the final step in gastric acid secretion. Research has explored whether this action might influence the overall acid load in the stomach.

Key Clinical Findings

Symptom Management

A large-scale Randomized Controlled Trial (RCT) reported that administering the drug at the dosage level evaluated was the focus of the study's examination of symptoms like heartburn and regurgitation over a multi-week period. Study monitoring for safety was conducted.

Cognitive Outcomes

Studies have been conducted to compare the drug's effect on working memory and other cognitive measures with traditional non-pharmacological interventions. Findings from observational studies regarding Omezol's long-term association with cognitive changes, such as dementia risk, have yielded mixed results, highlighting the need for more robust evidence from long-term randomized trials.

Dosage and Administration Protocol

Study protocols have often involved administering the dose 30 minutes before the first meal of the day. Research has examined the timing of symptom changes following administration, with some studies focusing on whether optimizing the dosing schedule affects symptom control.

Pharmacological Exploration and Study Scope

Research has explored the drug's mechanism and its potential relationship to drug interactions, particularly concerning medications metabolized by the CYP2C19 enzyme. Studies have noted that study populations did not consistently include individuals with certain pre-existing conditions, such as recent cardiovascular events, or that the drug's effects on the cardiovascular system were monitored during trials involving certain high-risk patient groups.

Key Studies & References

  1. Drug Interaction Profile of Proton Pump Inhibitors, Focusing on CYP2C19 Metabolism

Frequently Asked Questions (FAQ)

Common questions about Omezol (FAQ)


Q: Why is Omezol sometimes taken along with certain antibiotics?

Omeprazole is used alongside specific antibiotics, such as amoxicillin and clarithromycin, as part of a combination therapy. This regimen is indicated to treat and help prevent the return of ulcers caused by the H. pylori bacterium. The regulatory documents state that decreasing stomach acid helps to enhance the effectiveness of the antibiotics.


Q: Is it safe to stop taking Omezol suddenly after using it for a long time?

Official information suggests that discontinuing the use of the medicine after an extended period may be associated with a reaction known as rebound acid hypersecretion. This may cause a rapid return or worsening of reflux symptoms. For this reason, official information often describes a gradual reduction, or tapering, of the dose as a method examined for managing symptoms upon discontinuation.


Q: Can Omezol be taken 'as needed' for occasional symptoms, or must it be taken every day?

The over-the-counter (OTC) version of the medicine is specifically indicated for treating frequent heartburn, meaning symptoms that occur two or more days a week. According to regulatory labeling, it is instructed to be taken once daily for a 14-day course, not for immediate or 'as needed' relief of occasional symptoms.


Q: What are the signs of a possible allergic reaction to Omezol?

Serious adverse reactions that may signal an allergic or hypersensitivity response include symptoms like skin reddening, blistering, or rash. Official information notes that if these reactions occur, the use of the medicine is typically discontinued, and immediate medical attention is sought.


Q: What are the documented concerns about Omezol affecting anti-HIV medications?

Co-administration of Omeprazole is formally discouraged or contraindicated with certain antiretroviral medicines, including rilpivirine, nelfinavir, and atazanavir. Regulatory sources note that Omeprazole significantly reduces the amount of these drugs in the bloodstream. This happens because Omeprazole changes the stomach's pH, which is required for the proper absorption of those HIV medicines.


Q: What is the difference between prescription Omezol and the over-the-counter (OTC) version?

The OTC version is intended for self-treatment of frequent heartburn in adults aged 18 and older, following a specific 14-day course. In contrast, the prescription product is used for a broader range of conditions, often requiring longer treatment periods, and is taken under the guidance of a healthcare provider.


Q: What is the main purpose of Omezol when used for stomach ulcers?

Official drug information states that when Omezol is used to address stomach or intestinal ulcers, its main purpose is to decrease acid production. By significantly reducing the amount of acid in the stomach, the medicine establishes a healing environment, allowing the ulcers to recover.


Q: Why do official sources mention an increased risk of fundic gland polyps with long-term use?

Official labeling notes that using the medicine for an extended period of time may lead to the formation of fundic gland polyps (growths in the stomach). Regulatory sources describe these polyps as usually being benign, meaning they are not typically cancerous, and they often do not cause any noticeable symptoms.


Q: Is Omezol meant to be taken on an empty stomach or with food?

The official administration instructions generally direct that the oral dose should be taken before a meal. It is typically recommended to take the dose in the morning to maximize its effect.


Q: What are the potential signs of low Vitamin B12 due to long-term Omezol use?

Official information indicates that long-term use of the medicine may be linked to low levels of Vitamin B12. Symptoms associated with B12 deficiency can include tingling or numbness in the hands or feet, muscle weakness, confusion, or dizziness.


Q: Does taking Omezol affect the body's natural production of the hormone gastrin?

Studies and regulatory reviews indicate that the sustained acid suppression caused by the drug results in a rise in serum gastrin levels. This compensatory effect is reversible, meaning the elevation in gastrin generally decreases significantly once the drug is discontinued.


Q: What information is available regarding the effect of Omezol on the risk of stomach infections?

Official documentation notes that Omeprazole may increase the risk of a severe type of diarrhea called Clostridioides difficile-Associated Diarrhea (C. difficile). This infection affects the intestines and is listed as a potential complication in the adverse reactions section.


Q: Is there a link between Omezol use and dizziness or feeling light-headed?

Official adverse reaction lists include dizziness as a less common side effect reported by users. Dizziness and lightheadedness are also specifically noted on the OTC label as symptoms that may require immediate medical attention if they occur with heartburn.


Q: Does Omezol have known side effects that can affect the eyes or vision?

Regulatory reports indicate that side effects related to vision are rare. Blurred or decreased vision is listed as an incidence not known/rare side effect, and red, irritated eyes has also been reported in official documents.


Q: Can Omezol cause confusion or difficulty concentrating in rare cases?

Confusion has been listed as an uncommon adverse reaction in postmarketing reports. Additionally, official documents list both confusion and difficulty concentrating as potential signs associated with low Vitamin B12 levels, a known long-term risk of the drug.


Q: What is the official recommendation for taking Omezol if a patient is also taking Cilostazol?

Due to a documented drug interaction, regulatory documents note that a dose reduction of Cilostazol (e.g., to 50 mg twice daily) is often specified when co-administered with omeprazole, as omeprazole significantly increases Cilostazol's blood levels.


Q: Can Omezol cause changes in heart rhythm?

Although rare, long-term use of Omeprazole carries a risk of developing low serum magnesium levels, known as hypomagnesemia. Official safety communications state that low magnesium can potentially lead to serious side effects, including irregular heartbeat (arrhythmias) or a fast, racing, or uneven heartbeat.


Q: How is Omezol eliminated from the body?

Official pharmacological documents state that Omeprazole is extensively processed in the liver by specific enzyme systems, mainly CYP2C19 and CYP3A4. After being broken down, the resulting metabolites are primarily excreted from the body through the urine.


Q: Why is there a warning about taking Omezol if a patient has bloody, black, or tar-like stools?

The over-the-counter label advises against using the medication if a person has bloody, black, or tar-like stools. These symptoms are listed as potential indicators of a serious underlying medical condition, such as gastric malignancy, that requires immediate evaluation before starting treatment.


Q: Does Omezol stop all acid from being made in the stomach?

Omeprazole works by causing a profound and sustained suppression of gastric acid secretion. However, regulatory documents indicate that the effect lasts only until the stomach cell can synthesize new proton pumps; therefore, it does not completely eliminate all acid production.


Q: Does taking Omezol affect the results of the H. pylori breath test?

Official labeling states that the use of Omeprazole can produce false negative results in diagnostic tests for H. pylori, such as the breath test. For this reason, official labeling often notes that discontinuation of the medicine for a period before the test is performed is typical.


Q: Is it true that Omezol can cause changes in the taste sensation?

Official regulatory documents list taste disturbances as an adverse reaction. This side effect has been reported in clinical trials and post-marketing surveillance as an uncommon or rare event.

How should Omezol be stored and disposed of?

Omeprazole (Omezol) must be stored under specific conditions to maintain its stability, as mandated by regulatory authorities.

Storage Conditions

The medicine should be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), with the temperature generally not exceeding 30 C. It is mandatory to protect the product from moisture and light.

Packaging Rules

To ensure protection, the product must be kept in its original package or have the bottle tightly closed.

Stability Constraint

For products supplied in a bottle, the in-use shelf life is typically 100 days after first opening.

Disposal and Safety

Omeprazole must be stored out of the reach of children. Unused or expired medication should be disposed of in accordance with local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Omezol found in:

A-Z Index: